RxDoctor Payments Data

Mark Heckle, MD

Clinical Cardiac Electrophysiology · Cordova, TNNPI 1497190862

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (42.8%), grants and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Medtronic at 52.4% of the total. Reporting peaked in 2020 at $11,047 and has fallen 79.5% since, to $2,267 in 2025.

$29,057in general payments, 2019–2025

Across 422 payments — averaging $68.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$15K
  • Abbott$4K
  • Boston Scientific$3K
  • ZOLL Respicardia, Inc.$2K
  • Biosense Webster, Inc.$2K
  • Biotronik Inc.$1K
  • plus $2K from 10 others

What the payments were for

  • Grants$10,00034%
  • Travel & lodging$6,44922%
  • Food & beverage$12,43843%
  • Education$1701%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,057 in reported general payments places this provider in the 70th percentile of 82 clinical cardiac electrophysiology providers in Tennessee.

See all clinical cardiac electrophysiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$181,144
Medicare patients
714
Services billed
2,499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban463$376,745
XareltoRivaroxaban139$108,791
Propafenone Hcl ErPropafenone Hcl39$3,417
Dofetilide16$3,178
Metoprolol Succinate281$2,695
Amiodarone Hcl178$2,604
Flecainide Acetate69$2,273
Diltiazem 24hr Er (Xr)Diltiazem Hcl66$1,347
Dilt-XrDiltiazem Hcl55$1,109
SotalolSotalol Hcl54$882
Midodrine Hcl11$787
Diltiazem 24hr ErDiltiazem Hcl28$745
Propafenone Hcl19$717
Nebivolol Hcl19$696
Carvedilol83$554

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$49$376,745463 claims
Johnson & JohnsonXarelto$14$108,791139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 82 clinical cardiac electrophysiology providers in Tennessee.

Other clinical cardiac electrophysiology in Cordova

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →